Quantum Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Quantum Pharma Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10844
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Quantum Pharma Ltd (Quantum Pharma), a subsidiary Clinigen Group Plc, is a manufacturer and supplier of unlicensed medicines. The company develops, manufactures, and supplies niche pharmaceutical products. It offers dermatology products, branded generics and vitamins, borderline substances, short supply products, made-to-measure hosiery and dressings, coloplast ostomy products, veil cover cream, gluten-free breads, vennax, nabilone capsules, acetylcysteine, mediven stockings and jobst compression stockings. The company offers its products to retail pharmacy, pharmaceutical wholesaler, hospital, and homecare markets. Quantum Pharma is headquartered in Durham, the UK.

Quantum Pharma Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Quantum Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Quantum Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Quantum Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Quantum Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Quantum Pharma Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Quantum Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Quantum Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Private Equity 12
Apax Partners to Acquire neuraxpharm Arzneimittel from Atax and Neuraxpharm 12
Licensing Agreements 13
Quantum Pharma Enters into Licensing Agreement with Moorfields Pharma 13
Quantum Pharma Enters into Licensing Agreement with Futura Medical 14
German Pharma Company Enters into Licensing Agreement with Colonis Pharma 15
Quantum Pharma Enters into Licensing Agreements 16
Equity Offering 17
Quantum Pharma to Raise USD18.43 Million in Private Placement of shares 17
Quantum Pharma Raises USD167 Million in IPO 18
Acquisition 19
NuPharm Acquires Laboratoire Biodim from Pharma Omnium International 19
Clinigen Acquires Quantum Pharma for USD199 Million 20
Quantum Pharma Acquires NuPharm 22
Quantum Pharma Acquires Lamda, Lamda Labs and Lamda Pharma for USD10.4 million 23
Quantum Pharma Ltd – Key Competitors 24
Quantum Pharma Ltd – Key Employees 25
Quantum Pharma Ltd – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Aug 22, 2017: Quantum Pharma Announced Unaudited results for the half year ended 31 July 2017 27
May 03, 2017: Quantum Pharma Announces Final audited results for the year ended 31 January 2017 31
Other Significant Developments 32
Jun 26, 2017: Quantum Pharma: Disposal of Biodose Services and Trading Update 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Quantum Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Quantum Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Quantum Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Quantum Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Quantum Pharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Quantum Pharma Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Quantum Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Apax Partners to Acquire neuraxpharm Arzneimittel from Atax and Neuraxpharm 12
Quantum Pharma Enters into Licensing Agreement with Moorfields Pharma 13
Quantum Pharma Enters into Licensing Agreement with Futura Medical 14
German Pharma Company Enters into Licensing Agreement with Colonis Pharma 15
Quantum Pharma Enters into Licensing Agreements 16
Quantum Pharma to Raise USD18.43 Million in Private Placement of shares 17
Quantum Pharma Raises USD167 Million in IPO 18
NuPharm Acquires Laboratoire Biodim from Pharma Omnium International 19
Clinigen Acquires Quantum Pharma for USD199 Million 20
Quantum Pharma Acquires NuPharm 22
Quantum Pharma Acquires Lamda, Lamda Labs and Lamda Pharma for USD10.4 million 23
Quantum Pharma Ltd, Key Competitors 24
Quantum Pharma Ltd, Key Employees 25
Quantum Pharma Ltd, Subsidiaries 26

List of Figures
Quantum Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Quantum Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Quantum Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Quantum Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Quantum Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Quantum Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Quantum Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Quantum Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Quantum Pharma Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Quantum Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • General Motors Co (GM):企業の財務・戦略的SWOT分析
    General Motors Co (GM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • AFI Development plc:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' AFI Development plc Mergers and …
  • BELLUS Health Inc (BLU)-製薬・医療分野:企業M&A・提携分析
    Summary BELLUS Health Inc (BELLUS Health) is a biopharmaceutical development company, which focuses on developing drugs for rare diseases. The company’s pipeline products include BLU-5937 for chronic cough, Shigamab for STEC related hemolytic syndrome (sHUS); KIACTA for the treatment of a second ind …
  • Slovenske elektrarne, a.s.:企業のM&A・提携動向(発電分野)
    Summary Slovenske elektrarne, a.s. (Slovenske), a subsidiary of Enel Produzione S.p.A., is a electric utility company that generates, distributes and trades electricity. It also generates and markets heat and offers ancillary services to the power industry. The company generates electricity through …
  • Delta Oil & Gas, Inc. (DLTA):企業のM&A・提携動向(石油・ガス分野)
    Summary Delta Oil & Gas, Inc. (Delta) is an oil and gas company that explores, acquires, and develops oil and gas properties in Canada and North America. The company includes projects for natural gas and oil in the regions of Texas, Oklahoma, and California. It holds agreement with Sunset Exploratio …
  • Bonheur ASA (BON):企業の財務・戦略的SWOT分析
    Summary Bonheur ASA (Bonheur) is an oil and gas investment service provider that offers investment services for various energy sectors. The company invests in renewable energy, cruise, shipping and offshore wind, offshore drilling, and other investments. It operates shipping vessels for transport an …
  • Myriad Genetics Inc (MYGN)-医療機器分野:企業M&A・提携分析
    Summary Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that are designed to …
  • Care Service Co., Ltd. (2425):企業の財務及び戦略的SWOT分析
    Summary Care Service Co., Ltd. (Care Service) is a healthcare service company that offers nursing care services to patients and elderly people. The company provides services such as day care, and respite care for the senior citizens. Its nursing care division provides daycare services such as in-hom …
  • Intelligent Living Technologies Inc. (OXDG):企業概要、財務及び戦略的SWOT分析
    Summary Intelligent Living Technologies Inc. (ILTI) is a technology service provider. The company provides designs and implements energy efficient space for commercial and residential clients through lighting, window management, and automation solutions. It also concentrates in designing, supplying, …
  • Ryazan’nefteprodukt (RYAZ):企業概要、財務及び戦略的SWOT分析
    Summary Ryazan'nefteprodukt (Ryazannefteprodukt) is a Russia based oil retailing company. Ryazannefteprodukt is a subsidiary of TNK-BP, Russia. The company comprises of 64 oil retailing out-lets in Ryazan, Sasovo, Kasimov, Ryazhsk and Mikhaylov of Russian Federation. The company also has six oil sto …
  • Bavarian Nordic AS (BAVA)(製薬・医療分野):企業M&A動向
    Summary Bavarian Nordic A/S (Bavarian Nordic) is a biotechnology company. It is involved in developing product candidates to address cancer and infectious diseases. The company utilizes its technology platforms MVA-BN and VF-TRICOM to develop a wide range of products in the areas of cancer and infec …
  • Guangzhou Wondfo Biotech Co Ltd (300482)-医療機器分野:企業M&A・提携分析
    Summary Guangzhou Wondfo Biotech Co Ltd (Wondfo) is a biological company that provides rapid diagnostic services. The company manufactures medical products and biochemical reagents. Its products include rapid test, immunofluorescent test system, glucose monitoring system, and raw materials. Wondfo a …
  • Commtouch Software Ltd. (CYRN):企業概要、財務及び戦略的SWOT分析
    Summary Commtouch Software Ltd. (Commtouch) is an information technology service provider. The company develops and provides internet security technology and cloud-based services. It offers products and services which include email security suite, antivirus for NAS, antivirus for storage, antivirus …
  • Bank Alfalah Limited:企業の戦略・SWOT・財務分析
    SummaryBank Alfalah Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Fi …
  • South Egypt Drug Industries Co:企業の戦略的SWOT分析
    South Egypt Drug Industries Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Green Bridge Industries, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Green Bridge Industries, Inc. M …
  • Rigas Farmaceitiska Fabrika AS (FRM1R):企業概要、財務及び戦略的SWOT分析
    Summary Rigas Farmaceitiska Fabrika AS (RFF) is a pharmaceutical company. The company produces and supplies galenic preparations, soft pharmaceuticals and herbal drugs and tees. Its products include dermatologicals, respiratory system and immunity, alimentary tract and metabolism, musculo-skeletal s …
  • Cell Culture Technologies LLC(製薬・医療分野):企業M&A動向
    Summary Cell Culture Technologies LLC (Cell Culture) is a biotechnology company. The company provides mammalian cell culture systems for the production of recombinant proteins, monoclonal antibodies, and viral particles in protein. Its products include chomaster, turbodoma, invitrus, hektor, spodomi …
  • Tosoh Corporation:企業の戦略・SWOT・財務分析
    SummaryTosoh Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findi …
  • Nichi-Iko Pharmaceutical Co., Ltd. (4541):企業の財務及び戦略的SWOT分析
    Summary Nichi-Iko Pharmaceutical Co., Ltd. (Nichi-Iko) is a pharmaceutical company that develops, produces, exports and imports generic drugs. The company’s products include acarbose tablets, alacepril tablets, aluminum hydroxide gel, aranidipine capsules, bacampicillin hydrochloride tablets, barium …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆